Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)

Abscess, Intra-Abdominal Clinical Trial

Official title:
Clinical Effectiveness and Safety Study of Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)

Status Completed

Clinical Trial Summary

This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from a cIAI and take at least one dose of Moxifloxacin infusion.The primary objective is to define the types of cIAI infections that require Moxifloxacin i.v. therapy in China.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01096511
Study type	Observational
Source	Bayer
Contact
Status	Completed
Phase	N/A
Start date	December 2009
Completion date	January 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00629135` - Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses	Phase 3
Withdrawn	`NCT00463762` - Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.	Phase 4
Terminated	`NCT01110382` - A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections	Phase 3